Domestic leader in the field of mineralized collagen artificial bone repair materials: Aojing Medical is a national high-tech enterprise focusing on the R & D, production and sales of high-end biomedical materials and related medical devices.
Since its inception, the company has always been guided by the continuous innovation of products and technology to meet clinical needs, mainly focusing on the research and development of mineralized collagen artificial bone repair materials. In 2011, we launched the medical devices of mineralized collagen artificial bone repair materials, completed the clinical transformation and industrialization of mineralized collagen artificial bone repair materials, and established an in vitro biomimetic mineralization technology platform with complete intellectual property rights.
The market scale of orthopedic bone defect repair materials, oral bone implant materials and skull defect repair materials in China is expected to develop rapidly: the company's "skeletal gold", "tooth shell" and "cranial" products have all obtained the registration certificate of Class III medical devices in China. It has been used in bone defect repair in orthopaedics, oral or orthopaedic surgery and neurosurgery, and has been used in more than 100 hospitals, including many well-known third-class hospitals in China. More than one million cases of clinical use The "BonGold" product has become the first and only domestic artificial bone repair product in China that has obtained the market access license of FDA510 (k) in the United States. Affected by the aging population, the gradual increase in the permeability of dental implants in China and the increasing incidence of skull defects, the market scale of orthopaedic bone defect repair materials, oral bone implant materials and skull defect repair materials in China is expected to develop rapidly. The company is expected to seize the market quickly with the help of its technology, product and market layout, R & D team and system advantages. To achieve a rapid increase in the number of products. The company has also laid out a series of products under research for bone repair materials, which will continue to enrich the product line in the future.
Profit forecast: as a leading artificial bone repair enterprise in the industry, the company has high barriers to access and technology in the industry. with the in vitro biomimetic mineralization technology platform with complete intellectual property rights, diversified products and market layout, and multi-field compound R & D team, the company occupies a certain market space and has a positive impact on the company's future profitability. We estimate that the EPS of the company from 2021 to 2023 will be 0.93,1.25,1.70 yuan respectively, covering for the first time and without rating for the time being.
Risk hint: the risk of single product structure, product quality risk, new product research and development risk, competition pattern aggravates the risk.